The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus

Add time:09/03/2019    Source:sciencedirect.com

Glucokinase activators represent a promising potential treatment for patients with Type 2 diabetes. Herein, we report the identification and optimization of a series of novel indazole and pyrazolopyridine based activators leading to the identification of 4-(6-(azetidine-1-carbonyl)-5-fluoropyridin-3-yloxy)-2-ethyl-N-(5-methylpyrazin-2-yl)-2H-indazole-6-carboxamide (42) as a potent activator with favorable preclinical pharmacokinetic properties and in vivo efficacy.

We also recommend Trading Suppliers and Manufacturers of (3-Methylpyrazin-2-yl)-acetic acid ethyl ester (cas 15707-25-2). Pls Click Website Link as below: cas 15707-25-2 suppliers

Prev:Syntheses, structures, thermal stabilities and photoluminescent properties of three silver(I) complexes of 2-Ethyl-3-methylpyrazine (cas 15707-23-0) and different aromatic dicarboxylates with various silver units
Next:Research paperPolar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835)